BeiGene, Ltd. (BGNE)
After hours:
| Previous close | 163.27 |
| Open | 163.82 |
| Bid | 162.28 x 100 |
| Ask | 162.59 x 100 |
| Day's range | 161.70 - 165.26 |
| 52-week range | 126.97 - 225.23 |
| Volume | |
| Avg. volume | 206,680 |
| Market cap | 17.37B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.54 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 267.69 |
Business WireBeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
HOPEWELL, N.J., July 23, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center that further bolster the Company’s differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and
Business WireBeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
SAN MATEO, Calif., July 18, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition.
Simply Wall St.When Will BeiGene, Ltd. (NASDAQ:BGNE) Become Profitable?
BeiGene, Ltd. ( NASDAQ:BGNE ) is possibly approaching a major achievement in its business, so we would like to shine...
